case_images: PMC10949858_01
case_images: Timeline of treatment, Lorlatinib-related dyslipidemia and dissolving carotid plaque under lipid-lowering therapy (A-C).
case_images: fonc-14-1322501-g001.jpg
case_images: PMC10949858_01_fonc-14-1322501-g001.jpg
case_images: f1
case_images: The patient had no relevant family history to report.  Figure 1  holds information on relevant data from the episode of care, specific to our case report.Within a month after symptom onset, dyspnoea worsened so that the patient was unable to lie flat on her back. Subsequently, the patient had partial remission of NSCLC but developed an LDL-C driven dyslipidemia in need of lipid-lowering therapy ( Figure 1 ). In August of 2022 a routine health examination, which included carotid ultrasound, revealed a previously unknown asymptomatic left sided carotid artery plaque causing relevant stenosis which was confirmed in our neurovascular outpatient clinic ( Figure 1A ). Surprisingly, the left-sided internal carotid artery plaque dissolved accordingly. ( Figures 1B, C ).